Technologies

Pharmaceuticals & Vitamin D : Reproduction & infertility

Technologies

Protecting Ovaries from Chemotherapy Damage Using Proteasome Inhibitors

UW–Madison researchers have developed a method to reduce ovarian damage in cancer patients by administering a proteasome inhibitor prior to chemotherapy.

The inhibitors work by binding to a cell’s proteasome –the large complex of enzymes found in the cytoplasm that degrades and disposes old proteins. This binding action blocks chemotherapeutic agents from invading the cell nucleus.

To shield ovaries from chemotherapy toxicity, an effective dose of a proteasome inhibitor like bortezomib (Bort) or MG-132 is injected about an hour before treatment.
P130111US02